Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial  Catriona Parker, PhD, Shekhar Krishnan, FRCPath, Lina Hamadeh, PhD, Prof Julie A E Irving, PhD, Prof Roland P Kuiper, PhD, Prof Tamas Révész, FRACP, Prof Peter Hoogerbrugge, MD, Jeremy Hancock, PhD, Rosemary Sutton, PhD, Prof Anthony V Moorman, PhD, Prof Vaskar Saha, FRCPCH  The Lancet Haematology  Volume 6, Issue 4, Pages e204-e216 (April 2019) DOI: 10.1016/S2352-3026(19)30003-1 Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

Figure 1 Schematic showing outcome of patients with B-cell precursor-acute lymphoblastic leukaemia with late bone marrow relapses in the ALLR3 trial as per allocated treatment First complete remission refers to the time from completing front-line therapy. High minimal residual disease defined as ≥10−4 cells. Low minimal residual disease defined as <10−4 cells. SCT=stem-cell transplantation. The Lancet Haematology 2019 6, e204-e216DOI: (10.1016/S2352-3026(19)30003-1) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

Figure 2 5-year Kaplan-Meier estimates of (A) progression-free survival and (B) overall survival in patients with high and low minimal residual disease High minimal residual disease defined as ≥10−4 cells. Low minimal residual disease defined as <10−4 cells. The Lancet Haematology 2019 6, e204-e216DOI: (10.1016/S2352-3026(19)30003-1) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

Figure 3 Frequency of somatic copy number alterations and mutations according to (A) cytogenetic risk groups and (B) minimal residual disease at timepoint 1 High minimal residual disease defined as ≥10−4 cells. Low minimal residual disease defined as <10−4 cells. The Lancet Haematology 2019 6, e204-e216DOI: (10.1016/S2352-3026(19)30003-1) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions